Navigation Links
CIDP Treated With Plasma-Derived Therapy
Date:4/24/2009

Patients with rare, chronic inflammatory demyelinating polyneuropathy (CIDP) depend on plasma donation

ANNAPOLIS, Md., April 24 /PRNewswire/ -- Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating, progressive neurological disorder that results in muscle weakness and fatigue and can severely impair motor skills. According to the GBS/CIDP Foundation International, CIDP affects two to seven individuals per 100,000 worldwide. The rare disease is treated with intravenous immune globulin (IVIG), a plasma-derived therapy that replaces vital missing antibodies in a person's plasma and that is manufactured by member companies of the Plasma Protein Therapeutics Association (PPTA).

As recently reported in the news, William "The Refrigerator" Perry, a former Chicago Bears lineman, has been hospitalized for treatment of CIDP, which has brought this little known disease some recognition and spurred discussion about the illness and how it is treated in the news and among football fans.

IVIG also is the subject of legislation recently introduced in Congress, The Medicare Patient IVIG Access Act (S. 701 and H.R. 2002). The bills seek adequate reimbursement for IVIG therapy in all sites of care and to complete the hollow primary immunodeficiency disease (PIDD) home infusion benefit. If passed, S.701, introduced by Sens. John Kerry (D-MA) and Lamar Alexander (R-TN), and H.R. 2002, introduced by Reps. Steve Israel (D-NY) and Kevin Brady (R-TX), will improve access to treatment and enhance the quality of life for patients who encounter hurdles to accessing their lifesaving therapy.

PIDD is treated by infusing or injecting immune globulin therapy, which works to supplant a damaged or deficient immune system. According to the Immune Deficiency Foundation, the advocacy organization leading the support for the IVIG Access Act, about 55,000 individuals in the U.S. who are antibody deficient receive the therapy.

"IVIG is produced from plasma that is donated by healthy, committed donors across the nation," said Julie Birkofer, PPTA Vice President, North America. Plasma is the straw-colored, liquid portion of whole blood that remains when red blood cells, platelets and other cellular components are removed. It is rich in proteins needed to fight infection, clot blood, and ensure proper lung function.

Source plasma used to produce life-saving therapies like IVIG is donated by healthy, committed individuals at 380 government licensed and International Quality Plasma Program-certified plasma collections centers in the U.S., Europe and Canada.

"Across the country, tens of thousands of individuals rely on plasma protein therapies to treat rare, chronic diseases and disorders, which include hemophilia and other bleeding disorders, primary immunodeficiency diseases, alpha-1 antitrypsin deficiency, Kawasaki disease, and certain autoimmune and neurological disorders like CIDP," said Birkofer. "IVIG is a vital protein replacement therapy that treats diseases that are often life-threatening and always serious and chronic."

To learn more about lifesaving plasma protein therapies, visit www.pptaglobal.org. To find out how to become a plasma donor and become an important part of saving someone's life, visit www.donatingplasma.org. Visit www.gbs-cidp.org for more information about CIDP. For information about primary immunodeficiency disease, visit www.primaryimmune.org.

The Plasma Protein Therapeutics Association (PPTA) is the trade association and standard setting organization for the world's major producers of plasmaderived and recombinant analog therapies (collectively, "plasma protein therapies"). These therapies are used by more than 1 million people worldwide each year to treat a variety of diseases and serious medical conditions. PPTA members produce over 80 percent of the plasma therapies for the United States market and more than 60 percent worldwide. Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, immune globulin intravenous used to prevent infections in people with immune deficiencies and other serious conditions, and alpha1 proteinase inhibitor used to treat people with alpha1antitrypsin deficiency, also known as genetic emphysema.


'/>"/>
SOURCE Plasma Protein Therapeutics Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. First Patients Treated in India Using CyberKnife Radiosurgery
2. If You Treated an Illinois Workers Compensation Patient or a Patient Covered by an Illinois Automobile Insurance Policy and Your Bill was Reduced by a Discount Pursuant to a First Health or CCN PPO Network, Please Read This Notice Carefully As It Affects
3. Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study
4. Doctors call for change in how non-active TB in immigrant children treated
5. Teens Undertreated for Substance Abuse
6. Stroke treated significantly faster and just as safely by medical residents
7. Most HIV-Infected Prisoners Go Untreated After Release
8. First Dutch Patients Treated With the Percutaneous MitraClip(R) System
9. Pearly Penile Papule Patients Can Successfully Be Treated with Targeted CO2 Technology at La Jolla Cosmetic Surgery Centre
10. Georgia Ranks Fourth in the Number of Untreated HIV Patients in the United States
11. Penn study: Chances of surviving cardiac arrest depend on where patients are treated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, Doctors ... basis to help personal injury victims find high quality medical care. When the company ... Angeles area. Fast forward to present day and the now ten-page directory features a ...
(Date:12/2/2016)... ... 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland today ... spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched with ... caregivers the opportunity to share stories and advice, seek help, and continue their education ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... Wilmington, Delaware (PRWEB) , ... December 02, 2016 ... ... has released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite ... from sample entry through labeling, storing, shipping and disposal. The new version is ...
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that ... technology on the market can deliver all that rejiva can. , “Rejiva promotes relaxation ... health than the usual heart rate and steps taken”, adds Evens Augustin, CEO of ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition ... Demand Forecast to 2022" report to their offering. ... , , The ... and it is expected to grow at a CAGR of 5.5% during ... faster growth during the forecast period, a CAGR of 8.8% in the ...
(Date:12/2/2016)... , Dec. 2, 2016 Quantum Radiology,s Mobile ... expert radiologist interpretation directly to women at the workplace, ... corporations, such as Delta Air Lines and SunTrust Bank, ... as a component of wellness initiatives. "I ... SunTrust. It enables them to have a mammogram without ...
(Date:12/2/2016)... 2016 In the first ever attempt to ... derived from C. sativa, the Hebrew University in Jerusalem, ... Federico II , the Universita` del Piemonte Orientale and ... integrated and unified inventory of phytocannabinoids of different botanical ... the remarkable chemical and structural diversity of phytocannabinoids. As ...
Breaking Medicine Technology: